THE PROBLEM
Viral respiratory infections are transmitted through small pathogenic microbes carried by respiratory droplets. The most prevailing method used to combat these diseases is vaccination. COVID-19 vaccines, for example, have shown considerable effectiveness in preventing severe illness, hospitalization, and death. However, new SARS-CoV-2 variants have caused “breakthrough” infections in vaccinated people, necessitating the development of booster shots. In addition, vaccines work only after a vaccinated person’s immune system is triggered to respond.
Vaccines work poorly in the immunocompromised or with the elderly, and cannot be administered to certain populations such as the very young.
Moreover, regardless of vaccination status, some people who have been infected can experience a wide range of long-term health problems (Long COVID) which are not well understood.
The world needs a new approach to keep people safe from SARS-CoV-2 and other forms of known and new respiratory infections, from spreading it to others, and to reduce new variants with unknown properties from appearing.
OUR SOLUTION
InvisiShield’s strategy for defeating viral respiratory infections is to avoid getting infected by its causative virus in the first place.
InvisiShield has formulated an anti-SARS-CoV-2 nasal spray (IS101) to provide immediate protection against COVID-19 infection, regardless of a person’s vaccination or immune system status.
IS101 binds SARS-CoV-2 and has a proprietary retention technology. It “captures and kills” all current and potential future SARS-CoV-2 variants in the nasal cavity, the primary entry point of infection.
In pre-clinical studies, IS101 provided at least 10 hours of protection against infection in mice exposed to the highest viral load tested.
Our proprietary technology platform can also be applied to other respiratory viruses, including influenza and RSV. Leveraging this platform, we are developing a multi-disease combination spray that addresses SARS-CoV-2/influenza at the same time.
INTRODUCING THE INVISISHIELD™
INTRANASAL PREVENTIVE SPRAY PLATFORM
pathogen-engaging component
mucin interaction component
The InvisiShield™ Intranasal Preventive Spray Platform is our novel, proprietary technology platform designed to create pathogen-specific biomedicines for the prevention of airborne diseases, including COVID-19, flu, and the respiratory disease caused by RSV.
IS101, our anti-SARS-CoV-2 intranasal preventive spray, is our lead program generated with this platform.
We are also developing preventative sprays that "capture and kill" multiple viruses simultaneously, such as a SARS-CoV-2/influenza combination spray.
Our platform consists of a pathogen-engaging component that specifically recognizes and binds to disease-causing viruses or bacteria and a mucin-interaction component engineered with a proprietary retention technology that increases its retention on human mucosal surfaces, providing an extended period of protection.
InvisiShield Technologies’ projects in development include intranasal preventive sprays to provide prophylactic protection against influenza, which is responsible for 29 million illnesses and 35,000 deaths, and respiratory syncytial virus (RSV), which is responsible for 235,000 hospitalizations and 150,000 deaths in the US each year.
INVISISHIELD’S COVID-19
INTRANASAL PREVENTIVE SPRAY - IS101
IS101 has been formulated as an intranasal preventive spray for daily use to provide an important line of personal protection against SARS-CoV-2 infection.
Engineered with InvisiShield’s proprietary retention technology, IS101 electrostatically interacts with native mucin proteins in the nose, thereby coating the principal portal of viral entry with an “invisible shield”.
SARS-CoV-2 droplets or particles inhaled through the nasal passage will be captured by IS101.
In pre-clinical studies, IS101 provided at least 10 hours of protection against infection in mice exposed to the highest viral load tested.
1
Once applied, IS101 coats the nasal cavity as a protective shield
2
SARS-CoV-2 enters the upper respiratory tract
3
IS101 “captures and kills” the SARS-CoV-2 virus
IS101 PREVENTS INFECTION BY ALL COMMON SARS-COV-2 VARIANTS
In a cell-based assay model of SARS-CoV-2 infection, even at low concentrations, IS101 is still able to prevent infection by all common SARS-CoV-2 variants*.
*Based on studies performed using in vitro models of SARS-CoV-2 infection.
FREQUENTLY ASKED QUESTIONS
CURRENT STATUS
InvisiShield Technologies is preparing an Investigational New Drug (IND) application for IS101 with the U.S. Food and Drug Administration (FDA) to conduct clinical trials of the InvisiShield’s COVID-19 intranasal preventive spray.
For inquiries,
e-mail: info@invisishield.tech
